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Colorectal cancer progresses in a stepwise manner and is found to be linked with the 
accumulating mutations (Franks and Teich, 1993). The recent discovery found that the 
expression of human 20-kDa Myosin Light Chain (MLC-2) gene is downregulated in the 
tumour colon tissue compared to the normal colon tissue (Sim et al., 2006). The objective of 
this study is to screen for mutation in the MLC-2 gene of the normal and tumour samples by 
restriction endonucleases. Total RNA of both samples was used as the starting material and 
was transcribed into cDNA using M-MLV reverse transcriptase. The 251 bp MLC-2 gene was 
successfully amplified by polymerase chain reaction and was subsequently digested with 15 
different restriction endonucleases. The digestion yielded no abnormal cleavage of the MLC-2 
gene fragment between tumour and normal colon samples.  
 
Key words: Colorectal cancer, MLC-2 gene, gene expression, RT-PCR, restriction         
         endonuclease digestion. 
 
ABSTRAK 
Penyakit kanser usus besar meningkat secara bertahap dan didapati berhubangkait dengan 
mutasi yang terkumpul (Franks dan Teich, 1993). Pertemuan terkini melaporkan bahawa 
pengekspresan gen MLC-2 adalah lebih rendah didalam tisu usus besar tumor berbanding 
daripada tisu usus besar yang normal (Sim et al., 2006). Objektif kajian ini adalah untuk 
mencari mutasi di dalam gen MLC-2 antara tisu normal dan tisu tumor usus besar dengan 
kaedah penghadaman endonuklease pemotong. RNA kedua-dua samples di transkripsi 
terbalik ke cDNA mengunakan M-MLV transkriptase. Gen MLC-2 bersaiz 251 bp berjaya 
diamplifikasikan dan di potong dengan 15 enzim penghadam yang berlainan. Tiada 
pemotongan yang abnormal yang diperolehi antara dua sampel usus besar normal dan tumor.  
    
 
Kata kunci: Kanser usus besar, gen MLC-2, pengekspresan gen, RT-PCR , penghadaman  












 One of the leading silent diseases occurring among both men and women these days is 
colorectal cancer (CRC). Cancer can occur in any part of the colorectal system (Kumar and 
Clark, 1998). They are established from different forms and moves into different development 
stages of cancer – from benign to malignant neoplasms and the extent of its spread can be 
categorized based on whether it has moved into the inner layers of the colon, spread to nearby 
lymph nodes or to other organs (Cotran et al., 1999). The full disease mechanism and 
progression has yet to be fully understood and identified.  
 
 Genetic studies have been developed to identify the link of candidate causative or 
susceptibility genes to the progression of CRC. Mutational studies are common in screening 
for any genetic changes in a gene that might interfere to the gene’s regulation and expression 
or towards other processes of the cell (Church, 1996). Many different genes have been 
identified to be associated with CRC and some of the major colorectal cancer genes identified 
include APC, MCC, p53, DCC and ras genes (Cunningham and Dunlop, 1994). Therefore, 
studying a gene and its activity would provide an insight of a disease and its relationship.  
  
 The 20-kDa Human Myosin Light Chain 2 (MLC-2) gene was recently reported to be 
down-regulated in colorectal tumours (Sim et al., 2006). Its main function is in the contractile 
activity of smooth muscle and some non-muscle cells (Kumar et al., 1989). Previous studies 
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have reported that the down-regulation of MLC-2 could possibly be caused by chemical 
carcinogen (Kumar and Chang, 1992), virus infection (Kumar and Chang, 1992), mutation 
(Kabeva et al., 2002), or the binding of repressor element at transcription initiation site (Dhar 
et al., 1997; Kumar et al., 1989). Consequently, these could lead to the disruption of colon 
smooth muscle contraction and function. Hence, an initial screening was carried out in this 




The objective of this experiment is to isolate the human 20-kDa MLC-2 gene from normal 
colon tissue and tumour colon tissue and to subsequently screen for mutations or 




2.0 LITERATURE REVIEW 
2.1 Colorectal cancer 
 
 Colorectal system refers to the colon (large intestine) and rectum. The colon connects 
the small intestines to the rectum and can be divided into four sections – the ascending, 
transverse, descending and sigmoid part (Kumar and Clark, 1998). Four layers of tissues that 
construct the colon, from innermost to the outermost layer, are the mucosa, submucosa, 
muscularis proparia and serosa (Saladin, 1998; refer Figure 1). The muscle wall of the gut, 
which are the two layers of smooth muscles (Lippold and Cogdell, 1991) can however be 
divided into the inner circular layer and the outer longitudinal layer that works together to 















 The prevalence of colorectal cancer worldwide has been increasing in the past years. 
An estimated statistical number of cases and deaths due to CRC were reported by the National 
Cancer Institute, NCI (2007) which is about 153,760 new cases that will be diagnosed and 
52,180 deaths that will occur. In Malaysia, this disease represents 14.2% of the overall male 
cancers and 10.1% of the female cancers, ranking it as the first most common cancer amongst 
men and third among women (Lim and Yahaya, 2004). Symptoms of CRC include changes in 
bowel habits, bloody stools, fatigue, weight loss and anemia (Cotran et al., 1999). Diagnosis 
and screening of CRC can be carried out by barium enema, sigmoidoscopy, colonoscopy and 
imaging tests (Lum, 2007) and various treatments are available such as surgery, radiation 
therapy and chemotherapy; depending upon the CRC stage (Lum, 2007). Some of the risk 
factors of CRC are alcohol, diet, age, lifestyle, as well as inheritance factor (Franks and Teich, 
1993).  
 
 CRC can be divided into two groups – sporadic CRC cases which do not have a 
known family history of the cancer and familial CRC cases which are hereditary (Chapelle, 
2004). Familial cases can then be grouped based on presence or absence of polyps (mass of 
overgrown tissues), for example familial adenomatous polyposis (FAP) and hereditary non-
polyposis colon cancer (HNPCC), respectively (Chapelle, 2004). While there are different 
groups of CRC based on whether it is inherited or not, CRC can also be categorized based on 
the types of cells involved. The different types of cancer involving different cell types are 
carcinoma – ephitelial cells, melanoma – pigment-producing skin cells, sarcoma – bone, other 
connective tissue or muscle, leukemia – blood forming tissues, and lymphoma – lymph nodes 
(Saladin, 1998). According to the National Cancer Institute (2007), the most common type of 
CRC is adenocarcinomas, representing about 95% of occurrence which is usually derived 
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from epithelial cells. Colorectal cancer falls under the term ‘malignant disease’ and some of 
the causative factor that leads to the development of cancer in the colorectal is alcohol and 
diet (Kumar and Clark, 1998). Normal and tumour tissue differ in cell growth (Franks and 
Teich, 1993). Normal tissue continuing in growth leads to specialization and differentiation in 
both structure and function but tumour tissue are no longer responsive to the growth 
regulating mechanism (Frank and Teich, 1993).  
  
2.2 Genetics in CRC 
 
 The molecular-genetic perspective of CRC is its solid malignancy in regards to the 
extent of its accessibility in a patient whereby the different CRC stages of the same 
malignancy may co-exist within one patient (Simpson et al., 2005). Three presymptomatic 
screening and diagnosis of CRC that could be used to study a gene are genetic linkage 
analysis, mutation analysis and sequence analysis (Cunningham and Dunlop, 1994). The 
genetics behind colorectal carcinoma is that most of it is developed from stepwise 
progression, associated with the accumulating mutations in a number of growth-regulating 
genes (Franks and Teich, 1993). The type of genetic changes that may occur includes 
mutation in proto-oncogenes that would affect regulation of the normal cell division and 
differentiation, and inactivation of tumour suppressor genes that will cause excessive tumour 
growth (Kumar and Clark, 1998). However, changes in oncogenes and tumour suppressor 
genes may not always necessary be the cause to malignant transformation (Radtke and 
Clevers, 2005). The adenoma-carcinoma sequence model of tumour progression is often used 
to study CRC although it has yet to be fully proven for its reliability (Church, 1996). Three 
possible causes that could lead to colorectal tumour development are mutational activation of 
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oncogenes and inactivation of tumour suppressor genes, multiple mutations of a gene, or 
accumulated genetic alterations (Radtke and Clevers, 2005).  
  
 Mutations in genes and its link to CRC can be distinguished by either germline 
mutation which is in-born or somatic mutation (Cunningham and Dunlop, 1994). Such 
mutational changes would code either for an abnormal protein or none (Brooker, 1999). From 
the Human Gene Mutation Database, HGMD (Cooper et al., 2007), missense or nonsense 
mutations were found to be the most type of mutation found in genes associated with CRC. 
The overall type of mutation occurred most are in single nucleotide change of C to T – CAG 
to TAG (Gln to Term), CAA to TAA (Gln to Term), CGA to TGA (Arg to Term); and others 
– GAA to TAA (Glu to Term), TCA to TAA (Ser to Term), and TCA to TGA (Ser to Term) 
(Cooper et al., 2007). 
 
2.3 The 20-kDa MLC-2 gene and gene product 
  
 Myosin is one of the important components in the muscle tissues and is divided into 
two classes, which are the myosin heavy chain (MHC) and the myosin light chain (MLC) 
(Emery and Rimoin, 2002). The motor unit of the myosin is called the globular head, which 
carries the ATP binding site, and is made of two MHC and four MLC polypeptides (Emery 
and Rimoin, 2002). The MLC is categorized into two, namely the essential light chain (ELC), 
15-kDa, and regulatory light chain (RLC), 20-kDa (Emery and Rimoin, 2002). The human 20-
kDa MLC-2 gene (designated in this study as MLC-2 gene) is a type of protein coding gene, 
located on chromosome 20, locus HUMMLC2A, with 1120 bp mRNA (National Center for 
Biotechnology Information - NCBI, Accession Number J02854, last updated 1995).  
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 The gene product, MLC-2, functions in smooth muscle and non-muscle cell contractile 
activity (Kumar et al., 1989; Yamakita et al., 1994; Nishikawa and Hidaka, 1994), as well as 
stabilizing the alpha-helical neck that connects the head and rod which helps in preventing 
bending stress during contraction and relaxation (Emery and Rimoin, 2002). The 
phosphorylation of 20-kDa MLC-2 by myosin light chain kinase affects the function of 
myosin which was reported to be observable in its actin-activated ATPase activity (Chacko et 
al., 1985; Kumar et al., 1989). However, the exact mechanism governing the role of 
phosphorylated MLC-2 in actin-activated ATPase activity is yet to be explored. In colorectal 
tumour, disruption of colonic motility (control in contraction and relaxation) may be the cause 
of the symptoms observed in colorectal cancer patients and further lead to dangerous drop in 
blood pressure (Saladin, 1998). The contraction and relaxation of blood vessels, which are 
surrounded by smooth muscle cells, is important in regulating blood pressure and redirecting 
blood flow from one organ to another (Saladin, 1998).  
 
 Recently, the expression of MLC-2 gene has been reported to be down-regulated in 
colorectal tumours (Sim et al., 2006). Very little is known of the function of MLC-2 gene and 
its role in colorectal carcinoma. However, the expression of MLC-2 gene in different tissues 
has been reported to be caused by different factors. First, there is the repression of smooth 
muscle MLC-2 gene in human osteosarcoma cells which resulted in cell transformation when 
exposed to chemical carcinogen or infected by Kristen murine sarcoma virus (Kumar and 
Chang, 1992). In addition, studies have also shown that cardiac MLC-2 gene to undergo 
mutation at DNA and protein level to cause Hypertrophic Cardiomyopathy (HCM) (Kabeva et 
al., 2002) which is a condition of the heart muscle being thicker than normal (Emery and 
Rimoin, 2002). Besides that, according to the work by Kumar et al. (1989), the human smooth 
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muscle MLC-2 isoform is expressed restrictedly in smooth muscle tissues and in some non-
muscle cell lines, including those reported in normal colon tissue, but are not expressed in 
skeletal and cardiac muscles. Other works have suggested that two types of RLC isoform – 
RLC-A and RLC-B are present in smooth muscle and non-muscle tissues (Grant et al., 1990) 
but have not confirmed its specificity whereas cardiac MLC-2 is repressed in skeletal muscle 
by factor binding DNA elements (Dhar et al., 1997). These findings show tissue-specificity of 
MLC-2 gene and its gene product isoform in relation to the gene expression level (Nabeshima 




3.0  MATERIALS AND METHODS 
3.1 Samples 
Total RNA from colorectal samples of normal and tumour tissues were provided by Chia Sze 
Wooi from the Immunology Laboratory, Department of Molecular Biology, UNIMAS. The 
details of the samples are as stated in Table 1. 
 
Table 1: Details of RNA samples used 
RNA  
Sample 





CN03 1ug/ul Chemicon Asian; Healthy 
Tumour colon 
tissue 













3.2 Reverse Transcription 
Reverse transcription was carried out according to the protocol from Life Technologies 
Technical Product Information with certain modification. Four reverse transcription reaction 
was carried out for each colon total RNA samples – normal (CN03) and tumour (CT03); 
designated as CN03a, CN03b, CN03c, CN03d, CT03a, CT03b, CT03c and CT03d. The total 
RT-reaction volume prepared was 20 µl. Reagents in Table 2 were first added into a 0.5 µl 
microcentrifuge tube.  
 
Table 2: Reagents added before first incubation 
Reagents Volume (µl) 
Nuclease free water 11.5 
Random primer (Promega, USA) 1.0 
Total RNA 1.0 
Total  13.5 
 
 
Followed by the first incubation for ten minutes at 70˚C, quick chill on ice and a brief 
centrifugation before reagents in Table 3 were added. After that, it was incubated at 37˚C for 
one hour and subsequently at 70˚C for 15 minutes before the product was stored at -20˚C.  
 
Table 3: Reagents added before second incubation 
Reagents  Volume (µl) 
5X Reverse Transcription Buffer (Promega,USA) 4.0 
10 mM dNTPs (Promega, USA) 1.0 
40 U/µl RNase Inhibitor (Promega, USA) 0.5 
MMLV-Reverse Transcriptase (Promega, USA) 1.0 




3.3 Polymerase Chain Reaction (PCR) 
  
3.3.1 Primer design 
Two different sets of primers were used to flank the MLC-2 gene (refer Appendix 1). 
  
(a) Primer set 1 
Primer set 1 (First Base, Malaysia) flanks 1082 bp of the MLC-2 gene and was designed using 
FastPCR software. The calculated annealing temperature by the software is 65.7˚C.  
Forward primer 
(F1-primer) 
- 5’ ACTTCTTCGCACCAGGGAAGC 3’ 
   
Reverse primer 
(R1-primer) 
- 5’ CTGGACAGATGTCACGTCTGC 3’ 
 
   
  
(b) Primer set 2 
Primer specific for MLC-2 gene (primer set 2), designed by Ivyna Bong (personal 
communication) of the Immunology Laboratory, Department of Molecular Biology, 
UNIMAS) was used which flanks the sequence size of 251 bp. The calculated annealing 




- 5’ CATGATTGACCAGAACCGTG 3’ 
   
Reverse primer 
(R2-primer) 





3.3.2 Optimization of primer set one 
 
3.3.2.1    Gradient PCR 
Three sets of gradient PCR (G1, G2 and G3) was performed for optimization of MLC-2 gene 
with primer set one using Eppendorf-Mastercycler Gradient. Sets of 12 tubes were prepared 
and the annealing temperature range for gradient PCR was from 56.0°C to 68.5°C (set G1) 
and 50.0°C to 65.5°C (set G2 and G3).The PCR components added into a 0.2 µl PCR tube are 
as listed in Table 4 and the corresponding parameters applied are as stated in Table 5 and 
Table 6. Agarose gel electrophoresis was then performed for all 12 PCR products obtained 
and the remaining products were stored in -20˚C. 
 
Table 4: Gradient PCR mixture with primer set 1. 
Gradient PCR was performed three times (G1, G2 and G3) and differs in template cDNA amount and 
type as indicated in the table below. Taq polymerase (5 U/µl) (Fermentas, USA) was used for GI and 
G3 with its PCR buffer (Fermentas, USA) while GoTaq polymerase (1 U/µl) (Promega, USA) was 
used for G2 with its FlexiGreen Buffer (Promega, USA).  
 Volume (µl)  
PCR components 
G1 G2 G3 
Nuclease Free Water 17.3 14.0 17.0 
10X PCR Buffer 2.5 5.0 2.5 
25 mM MgCl2 (Fermentas, USA) 1.5 1.5 1.5 
10 mM dNTPs (Fermentas, USA) 0.5 0.5 0.5 
25 µM F1-primer 1.0 1.0 1.0 
25 µM R1-primer 1.0 1.0 1.0 
Taq polymerase  0.2 1.0 0.2 
Template cDNA 1.0  
 (CN03a) 
1.0   
(CN03b) 
1.5   
(CT03a) 








Table 5: Gradient PCR parameter for optimization of primer set 1.  
The PCR reaction was carried out using Eppendorf-Mastercycler Gradient. 
 G1 G2 G3 
Initial Denaturation 95°C   2 min 95°C   2 min 95°C   2 min 
35 cycle:  Denaturation 95°C   45 sec 95°C   45 sec 95°C   45 sec 
                Annealing 62 ± 6°C 
30 sec 
57.5 ± 7.5°C 
45 sec 
66.5 ± 7.5°C 
30 sec 
                Extension 72°C   2 min 72°C   110 sec 72°C   110 sec 
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